USD 7.30 billion
Osteoporosis Drugs Market Size, Share, Growth Analysis, By Drug Class(Branded, Generic), By Type(Bisphosphonates, Parathyroid Hormone, Calcitonin, Selective Estrogen Inhibitor Modulator), By Distribution Channel(Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2282 |
Region:
Global |
Published Date: October, 2024
Pages:
157
|Tables:
34
|Figures:
74
Osteoporosis Drugs Market Insights
Osteoporosis Drugs Market size was valued at USD 7.34 Billion in 2023 and is poised to grow from USD 7.59 Billion in 2024 to USD 9.92 Billion by 2032, growing at a CAGR of 3.40% during the forecast period (2025-2032).
The diagnosis, monitoring, and treatment of osteoporosis had become much better by virtue of the medical technologies, which included new medication delivery systems as well as devices used in measuring bone density. All of this contributes to an increase in the number of treatment options and better outcomes for patients towards improving the productivity of osteoporosis medications and thus its future prospects in the market. The osteoporosis drugs are specifically meant for prevention, treatment, or management of the disease, which is characterized by reduced bone mass and a consequent increase in the fragility of bones and susceptibility to fractures. These medications work to improve bone strength, slow down bone loss, and lower the risk of osteoporosis-related fractures. Medications intended for osteoporosis improve the quality of bone health while reducing the risk of fracture by inhibiting bone resorption, which is considered being the breakdown of bone tissue, and promoting the manufacture of new bones.
Numerous reasons are contributing to the development of the market, such as continued advances in drug discovery and the increased demand for integrated digital health solutions, enhanced attention on fracture prevention, and the ever-increasing rationalization with biologic medicines. Biologic medicines, including monoclonal antibodies that target key regulators of bone metabolism, are potentially effective treatment approaches against osteoporosis. Such medications might provide alternatives for patients who do not respond to traditional treatment or have intolerable side effects since their modes of action are more directed. Additionally, osteoporosis research and medication development are utilizing machine learning technology and artificial intelligence (AI) in healthcare.
US Osteoporosis Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
bisphosphonates
Fastest Growth
bisphosphonates
Growth Rate
5.96% CAGR
Global Osteoporosis Drugs Market ($ Bn)
Country Share by North America (%)
To get more reports on the above market click here to Buy The Report
Osteoporosis Drugs Market Segmental Analysis
Global Osteoporosis Drugs Market is segmented by Drug Class, Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Branded, and Generic. Based on Type, the market is segmented into Bisphosphonates, Parathyroid Hormone, Calcitonin, Selective Estrogen Inhibitor Modulator, Rank Ligand Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Analysis by Drug Class
As per categorization by drug class, the market is classified as bisphosphonates, selective estrogen inhibitors modulator, parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Among these, rank ligand inhibitors earned the largest share and continue to hold the dominant global osteoporosis drugs market share. Rank ligand inhibitors are revolutionizing the global osteoporosis drugs market due to their targeted mechanism in preventing bone loss by inhibiting osteoclast formation. This enhances efficacy and safety in denosumab and other inhibitors, making them arguably superior to effective conventional therapy. The superior efficacy of this treatment is magnified by a very high potential reduction in fracture risks in patients with osteoporosis and the spread of usage by an increasing aging population, improved diagnostic rates, and worldwide growing healthcare awareness.
Bisphosphonates are poised to be the fastest-growing segment in the global osteoporosis drugs market due to their proven ability to prevent bone density loss by inhibiting bone resorption. This is the reason why they continue to be accessible, affordable, and in widespread use, particularly in developing markets. Their formulation advances, including once-a-week or once-a-month dosing, increase compliance. Elimination of the global aging population along with osteoporotic individuals and increasing healthcare emphasis on early diagnosis and treatment is an important part of the growing trend. Continuing research on improving the methods of delivery also adds to their overall attraction, thus cementing their place in the ever-growing osteoporosis market.
Analysis by Route of Administration
The oral route of administration dominates the global osteoporosis drugs market due to its convenience, cost-effectiveness, and patient-friendly nature. Extended-release formulations and combination regimens are developed to enhance therapeutic benefit while reducing the adverse effect. Bisphosphonates are referred to as by far the most important drugs in the management of osteoporosis, and the oral route is thus gaining popularity. The fact that this self-administered route reduces dependency on healthcare facilities improves adherence and accessibility, especially in many resource-limited settings. Its universal acceptance by patients and healthcare providers, at the same time with fast-moving progress in drug delivery technologies, will maintain its position as a leading route for treatment of osteoporosis in this growing market for patients demand all over the world for more effective treatments.
The injectable route of administration is projected to be the fastest-growing segment in the global osteoporosis drugs market due to its ability to deliver targeted, long-lasting treatments. Injectable agents like rank ligand inhibitors and anabolic agents represent examples-such as teriparatide and romosozumab-which fall within the category of drugs showing better efficacious fracture risk reduction and improved stimulation of bone formation. In general, injectable therapy is compatible with severe cases and in patients who are poor responders to oral agents. New technologies for pre-filled syringes and auto-injectors increase convenience and adherence to treatment. More significantly, the increasing burden of osteoporosis, coupled with a growing preference among healthcare providers toward injectables, grows this segment as a key factor of the global osteoporosis drugs market growth.
Global Osteoporosis Drugs Market By Drug Class (%)
To get detailed analysis on other segments, Request For Free Sample Report
Osteoporosis Drugs Market Regional Insights
North America dominates the global osteoporosis drugs market due to its advanced healthcare infrastructure, high awareness of osteoporosis, and strong focus on early diagnosis and treatment. Real investments develop into research and development and have hence boosted the rapid embrace of some highly innovative therapy agents, such as Rank Ligand Inhibitors and anabolic agents. Aging and high incidence rates of osteoporosis-related fractures further fuel demand. Other elements that build patient uptake include very good reimbursement policies and access to advanced diagnostic tools. Collaboration between pharmaceutical companies and regulatory bodies and health care providers creates a strong channel for new osteoporosis agents to the market, hence consolidating the leadership of North America.
Asia Pacific is the fastest-growing region in the global osteoporosis drugs market due to its rapidly aging population and increasing prevalence of osteoporosis-related conditions. Early detection as well as intervention are driven by increased health awareness and enhanced access to high diagnostic tools. Economic growth and expansive healthcare infrastructure in nations like China, Japan, and India are promoting drug uptake. In addition, government initiatives and health advocacy targeting osteoporosis stimulate market opportunities for pharmaceutical companies. The continually increasing accessibility and affordability of generic drugs, together with big investments for R&D, help improve the market driving factor that is placing Asia Pacific as a dynamic developing and profitable region regarding osteoporosis treatments.
Global Osteoporosis Drugs Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Osteoporosis Drugs Market Dynamics
Osteoporosis Drugs Market Drivers
Aging Population Driving Demand
-
The aging population across the globe is the major factor behind the increasing global osteoporosis drugs market size, as older adults stand a significant risk for bone density loss and fractures. This change in demographics will increase the prevalence of osteoporosis and consequently the demand for effective treatment for bone improvement, which will, in turn, encourage economic burdens from fractures.
Advancements in Therapeutic Innovations
-
Innovations that include new drug development in targeted therapies such as Rank Ligand Inhibitors and anabolic agents are boosting the market further. It gives improved efficacy, reduced side effects, and unmet needs of osteoporosis management treatment. Better formulations such as extended-release formulations and injectables are also expected to support increasing penetration among patients and healthcare providers on a global scale.
Osteoporosis Drugs Market Restraints
Side Effects and Safety Concerns
-
Certain osteoporosis drugs, particularly bisphosphonates and anabolic agents, are associated with side effects like gastrointestinal issues and osteonecrosis of the jaw. These safety concerns often lead to poor patient adherence and limit the long-term use of treatments, restricting the market’s potential and influencing healthcare providers' prescribing practices.
Regulatory and Approval Challenges
-
This can pose regulatory obstacles for the approval of new osteoporosis drugs, which can slow entry into the market. In addition, due to the high cost of conducting clinical trials, the introduction of new treatment modalities and new medicines is severely restricted, thus limiting both and restricting overall market growth.
Request Free Customization of this report to help us to meet your business objectives.
Osteoporosis Drugs Market Competitive Landscape
The global osteoporosis drugs market is highly competitive, with several pharmaceutical giants dominating the landscape. For instance, there are major players including Amgen, Novartis, Eli Lilly and Sanofi which lead in bringing into the market innovative therapies including Rank Ligand Inhibitors, bisphosphonates and anabolic agents. They are interested in diversifying product portfolios, research and development and increasing patient access through various formulations to impact the market. There is more collaboration and partnership within the market competition that intensifies in favor of proving treatment solutions to meet the rising demand for effective treatment for osteoporosis.
Osteoporosis Drugs Market Top Player’s Company Profiles
- Amgen Inc. (US)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Novartis International AG (Switzerland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Radius Health, Inc. (US)
- UCB S.A. (Belgium)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Roche Holding AG (Switzerland)
- Bristol-Myers Squibb Company (US)
- Sanofi S.A. (France)
- AbbVie Inc. (US)
- AstraZeneca PLC (UK)
- Hologic, Inc. (US)
- Lundbeck A/S (Denmark)
- Eisai Co., Ltd. (Japan)
- Ferring Pharmaceuticals (Switzerland)
- Sandoz International GmbH (Switzerland)
- Servier Laboratories (France)
- Bayer AG (Germany)
- Grunenthal GmbH (Germany)
Osteoporosis Drugs Market Recent Developments
- In October 2024, Amgen announced its ever green-phased successful completion of the new Phase III clinical trial for osteoporosis drugs Evenity (romosozumab). The study brought significant improvements in reducing fractures among postmenopausal women with osteoporosis. It aims further to improve the effect of the drug by increasing treatment options for high-risk patients and continuing global regulatory approvals.
- In September 2024, Eli Lilly launched an all-new formulation, by the name of Forteo (teriparatide) for easy administration. This new injectable form is aimed at effective patient adherence in order to broaden the scope of osteoporosis treatment. The company has earmarked efforts at making this condition more affordable and accessible, especially in emerging markets with limited treatment options.
- In August 2024, Novartis received approval from the European Medicines Agency for its new bisphosphonate-based drug targeting bone strength in osteoporotic patients. This drug is designed to reduce the frequency of fractures by strengthening bone mineral density. Novartis is expanding its presence in the osteoporosis market, especially in Europe and Asia.
Osteoporosis Drugs Key Market Trends
- Increasing Adoption of Injectable Therapies: Injectable therapies, for example, the Rank Ligand Inhibitors and anabolic agents, have gained a lot of attention from the effect they produce and the lasting period. These therapies fit the profile of treating patients for severe osteoporosis, hence feeding the increased demand for injectable drugs in the global osteoporosis market.
- Rising Focus on Personalized Osteoporosis Treatment: There is a steady movement toward personalization of osteoporosis therapy, fueled by genetic research as well as patient-specific diagnostics. Advances in both genetic research and patient-specific diagnostics have seen the emergence of personalized management of osteoporosis conditions. More effective condition management is achieved through personalized therapy according to risk profiles, improved outcomes, and hence an increased need for targeted osteoporosis medication globally.
Osteoporosis Drugs Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, rapidly growing osteoporosis drugs industry is fostered by continuous development in drug therapies, better diagnostic tools, and newer delivery methods to enhance treatment. It is now proving effective as an improvement in the biologics treatment injectable personal therapy will enable better compliance with treatment.
Furthermore, the increasing incidence of osteoporosis in the aged demographic worldwide continues to drive the demand for effective medicines. Although there are still challenges such as safety issues and regulatory issues, much ongoing research and integration of new technologies are forming a very bright future for this market through better management options and improved outcomes to patients globally.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 7.1 billion |
| Market size value in 2031 | USD 9.59 billion |
| Growth Rate | 3.40% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Osteoporosis Drugs Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Osteoporosis Drugs Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Osteoporosis Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Osteoporosis Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Osteoporosis Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Osteoporosis Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
